Solid-State Characterization and Dissolution Properties of Lovastatin Hydroxypropyl-β-Cyclodextrin Inclusion Complex - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Solid-State Characterization and Dissolution Properties of Lovastatin Hydroxypropyl-β-Cyclodextrin Inclusion Complex
The objectives of this study were to prepare and characterize inclusion complexes of lovastatin with hydroxypropyl-β-cyclodextrin (HPβ-CD) and to study the effect of the complexes on the dissolution rate of lovastatin (LVS). The findings suggest that LVS's poor dissolution profile can be overcome by preparing its inclusion complex with HPβ-CD.


Pharmaceutical Technology


25. L. Chengsheng, L. Chenguang, and H.D. Kashappa, "Enhancement of Dissolution Rate of Valdecoxib Using Solid Dispersions with Polyethylene Glycol 4000," Drug Dev. Ind. Pharm. 31 (1), 1–10 (2005).

26. A.R. Hedges. "Industrial Applications of Cyclodextrins," Chemical Reviews 98 (5), 2035–2044 (1998).

27. T. Pralhad and K. Rajendrakumar, "Study of Freeze-Dried Quercetincyclodextrin Binary Systems by DSC, FT-IR, X-ray Diffraction and SEM Analysis," J. Pharm. Biomed. Anal. 34 (2), 333–339 (2004).

28. R.O. Williams, V. Mahaguna, and M. Sriwongjanya, "Characterization of an Inclusion Complex of Cholesterol and Hydroxypropyl-bcyclodextrin," Eur. J. Pharm. Biopharm. 46 (3), 355–360 (1998).

29. R.K. McMullan et al., "Topography of Cyclodextrin Inclusion Complexes: Part I. Classification of Crystallographic Data of α-Cyclodextrin Inclusion Complexes,"Carbohydr. Res. 31 (1), 37–46 (1973).

30. D. Horter and J. B. Dressman, "Influence of Physiochemical Properties on Dissolution of Drugs in the Gastrointestinal Tract," Advanced Drug Delivery Reviews 25 (1), 3–14 (1997).

31. J. P. Skelly et al., "Scale Up of Immediate Release Oral Solid Dosage Forms," J. Parenter. Sci. Technol. 47 (2), 52–56 (1993).

32. E. Galia, J. Horton, and J.B. Dressman, "Albendazole Generics—A Comparative In Vitro Study," Pharm. Res. 16 (12), 1871–1875 (1999).

33. C. Noory et al., "Rethinking the Use of Water as a Dissolution Medium," Dissolution Technol. 6 (4), 6–7 (1999).

34. V. P. Shah et al., "In Vitro Dissolution of Sparingly Water-Soluble Drug Dosage Forms," Int. J. of Pharm. 125 (11), 99–106 (1995).

35. M. Barzegar-Jalali et al., "Enhancement of Dissolution Rate and Anti-Inflammatory Effects of Piroxicam Using Solvent Deposition Technique," Drug Dev. Ind. Pharm. 28 (6), 681–686 (2002).

36. L. Tang, S.U. Khan, and N.A. Muhmmad, "Evaluation and Selection of Bio-relevant Dissolution Media for a Poorly Water Soluble New Chemical Entity," Pharm. Develop. Technol. 6 (44), 531–540 (2001).

37. H. Vromans, A.C. Eisson, and F.L. Coenraad, "Mechanism of Dissolution of Drug-Cyclodextrin Complexes," Drug Dev. Ind. Pharm. 15, 250–255 (1989).

38. M.E. Aulton, "Pharmaceutical Technology," in: Pharmaceutics: The Science of Dosage Form Design (London, UK: Churchill Livingstone, 1988), pp. 600–616.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here